Centene unloaded PANTHERx and Magellan Rx on Thursday, as part of a portfolio rationalization the government-sponsored managed care giant is executing under new leadership.
Driving the news: Three months after Axios first reported the divestiture processes had launched for both assets, Centene is selling the pair for a combined $2.8 billion.
